St. Michael's Financial<p>🔬 Biotech may have stumbled in FY25—but opportunity is building for FY26.</p><p>HB Biotechnology posted 23% outperformance in one of the toughest years for the sector. At St. Michaels Financial Services, we explore why strong fundamentals, thoughtful diversification, and regulatory shifts could drive a biotech rebound.</p><p><a href="https://medium.com/@st.michaels.financial.serivces/biotechs-underrated-upside-positioning-for-opportunity-in-fy26-120e7ed2b432" rel="nofollow noopener" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">medium.com/@st.michaels.financ</span><span class="invisible">ial.serivces/biotechs-underrated-upside-positioning-for-opportunity-in-fy26-120e7ed2b432</span></a></p><p><a href="https://mastodon.social/tags/Biotech" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>Biotech</span></a> <a href="https://mastodon.social/tags/Investing" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>Investing</span></a> <a href="https://mastodon.social/tags/FinancialStrategy" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>FinancialStrategy</span></a> <a href="https://mastodon.social/tags/Markets" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>Markets</span></a> <a href="https://mastodon.social/tags/WealthManagement" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>WealthManagement</span></a> <a href="https://mastodon.social/tags/StMichaelsFinancial" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>StMichaelsFinancial</span></a> <a href="https://mastodon.social/tags/HealthcareEquities" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>HealthcareEquities</span></a></p>